Brief: CURE Pharmaceutical Augments Its Existing U.S. DEA License
23/03/2021 12:42
March 23 (Reuters) - Cure Pharmaceutical Holding Corp
CURR.PK :
* CURE PHARMACEUTICAL AUGMENTS ITS EXISTING U.S. DEA LICENSE
IN
ORDER TO INITIATE DEVELOPMENT OF ITS PSYCHEDELICS-BASED
PHARMACEUTICAL CLINICAL PIPELINE
Source text for Eikon: ID:nBw9G1cJya
Further company coverage: CURR.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avenir Wellness Solutions
See all newsBrief: Cure Pharmaceutical Reports Q2 2022 Results
Brief: Cure Pharmaceutical Announces Rob Davidson As New Chairman Of The Board And Appointment Of Rob Costantino As Member Of The Board And Audit Committee Chairman
Brief: Cure Pharmaceutical Holding Q1 Revenue $1.5 Million
Brief: CURE Pharmaceutical Augments Its Existing U.S. DEA License
Brief: Cure Pharmaceutical Receives FDA Approval For Its IND Application For Curefilm Blue